Skip to main content
NCBI home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1994 Mar;70(3):237–240. doi: 10.1136/adc.70.3.237

Peripheral blood stem cells used to augment autologous bone marrow transplantation.

P L Mitchell 1, V B Shepherd 1, H M Proctor 1, M Dainton 1, S D Cabral 1, C R Pinkerton 1
PMCID: PMC1029751  PMID: 7907853

Abstract

Peripheral blood stem cells (PBSC) were used to augment autologous bone marrow transplantation (ABMT), aiming to hasten engraftment after high dose treatment in a group of heavily pretreated patients. PBSC were obtained by leukapheresis during the rebound after standard chemotherapy. In 11 patients aged 7-17 years, high dose chemotherapy consisted of busulphan 16 mg/kg orally with melphalan 160 mg/m2 intravenously for seven patients, and melphalan 200 mg/m2 intravenously alone for four. The median number of granulocyte-macrophage colony forming units in the reinfused PBSC was 3.42 x 10(4)/kg (3.03-18.01) and bone marrow 12.4 x 10(4)/kg (4.16-28.6). Neutrophil recovery to > or = 0.5 x 10(9)/l and platelet transfusion independence occurred at a median of 14 days (11-18) and 22 days (9-84) respectively. In five patients the early engraftment was transient with neutrophils again dropping below 0.5 x 10(9)/l then slowly recovering. There was one toxic death due to sepsis. PBSC harvesting in these children was undertaken without interrupting routine chemotherapy and without the use of bone marrow growth factors. In some patients PBSC failed to influence engraftment and the use of combined chemotherapy and growth factor priming for PBSC collection may give improved results.

Full text

PDF
237

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Emminger W., Emminger-Schmidmeier W., Höcker P., Gerhartl C., Kundi M., Gadner H. The median daily increment of leukocytes during hematopoietic recovery reflects the myeloid progenitor cell yield during leukapheresis in children. Bone Marrow Transplant. 1990 Jun;5(6):419–424. [PubMed] [Google Scholar]
  2. Fernandez J. M., Shepherd V., Millar J., Powles R., Pinkerton C. R. When is the optimum time to harvest peripheral blood stem cells in children following standard dose chemotherapy? Med Pediatr Oncol. 1993;21(7):465–469. doi: 10.1002/mpo.2950210702. [DOI] [PubMed] [Google Scholar]
  3. Fukuda M., Kojima S., Matsumoto K., Matsuyama T. Autotransplantation of peripheral blood stem cells mobilized by chemotherapy and recombinant human granulocyte colony-stimulating factor in childhood neuroblastoma and non-Hodgkin's lymphoma. Br J Haematol. 1992 Mar;80(3):327–331. doi: 10.1111/j.1365-2141.1992.tb08140.x. [DOI] [PubMed] [Google Scholar]
  4. Gianni A. M., Bregni M., Siena S., Villa S., Sciorelli G. A., Ravagnani F., Pellegris G., Bonadonna G. Rapid and complete hemopoietic reconstitution following combined transplantation of autologous blood and bone marrow cells. A changing role for high dose chemo-radiotherapy? Hematol Oncol. 1989 Mar-Apr;7(2):139–148. doi: 10.1002/hon.2900070205. [DOI] [PubMed] [Google Scholar]
  5. Haas R., Hohaus S., Egerer G., Ehrhardt R., Witt B., Hunstein W. Recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) subsequent to chemotherapy improves collection of blood stem cells for autografting in patients not eligible for bone marrow harvest. Bone Marrow Transplant. 1992 Jun;9(6):459–465. [PubMed] [Google Scholar]
  6. Kawano Y., Takaue Y., Saito S., Sato J., Shimizu T., Suzue T., Hirao A., Okamoto Y., Abe T., Watanabe T. Granulocyte colony-stimulating factor (CSF), macrophage-CSF, granulocyte-macrophage CSF, interleukin-3, and interleukin-6 levels in sera from children undergoing blood stem cell autografts. Blood. 1993 Feb 1;81(3):856–860. [PubMed] [Google Scholar]
  7. Lowry P. A., Tabbara I. A. Peripheral hematopoietic stem cell transplantation: current concepts. Exp Hematol. 1992 Sep;20(8):937–942. [PubMed] [Google Scholar]
  8. Mihich E., Hemler M. E. Adhesion molecules: cellular recognition mechanisms. The Pezcoller Foundation Symposia, Rovereto, June 24-26, 1992. Ann Oncol. 1993 Aug;4(7):545–547. doi: 10.1093/oxfordjournals.annonc.a058585. [DOI] [PubMed] [Google Scholar]
  9. Richman C. M., Weiner R. S., Yankee R. A. Increase in circulating stem cells following chemotherapy in man. Blood. 1976 Jun;47(6):1031–1039. [PubMed] [Google Scholar]
  10. Shea T. C., Mason J. R., Storniolo A. M., Newton B., Breslin M., Mullen M., Ward D. M., Miller L., Christian M., Taetle R. Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy. J Clin Oncol. 1992 Mar;10(3):464–473. doi: 10.1200/JCO.1992.10.3.464. [DOI] [PubMed] [Google Scholar]
  11. To L. B., Roberts M. M., Haylock D. N., Dyson P. G., Branford A. L., Thorp D., Ho J. Q., Dart G. W., Horvath N., Davy M. L. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant. 1992 Apr;9(4):277–284. [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES